A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease

Study Status: 
Study Description: 

What is the purpose of this study?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BMS241027, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called tau, in the fluid surrounding the brain. We hope that BMS241027 can decrease the levels of tau.


Who is eligible?

We are looking for participants who:

-- have been diagnosed with mild Alzheimer's disease

-- are between the age of 50 and 90

-- have a reliable caregiver or family member who is able to accompany them to study visits

-- are in stable medical condition

-- are willing to undergo MRI and lumbar punctures


People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study.


Please see the attached study description for more information.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

BMS web blurb.doc37 KB